Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

The film “Lilly,” a biopic about the equal pay icon Lilly Ledbetter, lands in theaters at a difficult time for her biggest ...

President Donald Trump's executive order mandates drugmakers to lower prices to match those in affluent nations, threatening ...

U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion investment in the United ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

President Donald Trump’s latest bid to slash prescription drug prices has once again stirred heated debate about the high ...

Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9< ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...